Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis DOI
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(2)

Published: Dec. 30, 2024

Type 2 diabetes (T2D), as well obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The impacts of glucose-lowering weight-lowering drugs their potential benefits in preventing CKD often guide clinicians choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available the effects safety profile tirzepatide. To explore tirzepatide vs controls. RCTs involving patients receiving any indication intervention arm placebo or active comparator control were searched through multiple electronic databases. co-primary outcomes percent change from baseline (CFB) urine albumin-to-creatinine ratio (UACR) absolute CFB estimated glomerular filtration rate (eGFR; mL/min/1.73 m2); secondary outcome was tirzepatide's profile. RevMan web used to conduct meta-analysis using random-effects models. Outcomes presented mean differences (MD) ratios with 95% confidence intervals. Fifteen (n = 14471) mostly low bias (RoB) included. Over 26-72 weeks, 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] 15 -18.03% (-28.58, -7.47), 0.0008] superior reductions UACR. Tirzepatide, at all doses, outperformed insulin Compared placebo, UACR reduction greater subjects T2D than those obesity but without (MD -33.25% -7.93%; 0.001). eGFR doses comparable [5 mg: MD 0.36 (-1.41, 2.14); 1.17 (-0.22, 2.56); 1.42 (-0.04, 2.88)]; > 0.05 all] insulin. Tirzepatide (pooled separate doses) did not increase risks adverse events, urinary tract infection, nephrolithiasis, acute injury, cancer compared insulin, glucagon-like peptide-1 receptor agonists. Short-term RoB suggests that positively detrimental T2D, a reassuring Larger warranted prove longer-term tirzepatide, which might also prevent decline worsening CKD.

Language: Английский

Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention DOI
Annunziata Nusca,

Maria Pia Di Bitonto,

A. Spanò

et al.

The American Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future DOI Creative Commons
Ying Jie Chee, Rinkoo Dalan

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1386 - 1386

Published: June 21, 2024

Cardiovascular disease (CVD) and kidney are the main causes of morbidity mortality in type 2 diabetes mellitus (T2DM). Globally, incidence T2DM continues to rise. A substantial increase burden CVD renal disease, alongside socioeconomic implications, would be anticipated. Adopting a purely glucose-centric approach focusing only on glycemic targets is no longer adequate mitigate cardiovascular risks T2DM. In past decade, significant advancement has been achieved expanding pharmaceutical options for T2DM, with novel agents such as sodium-glucose cotransporter (SGLT2) inhibitors glucagon-like peptide receptor agonists (GLP-1 RAs) demonstrating robust evidence cardiorenal protection. Combinatorial approaches comprising multiple pharmacotherapies combined single agent an emerging promising way not enhance patient adherence improve control but also achieve potential synergistic effects greater this review, we provide update antidiabetic appraisal mechanisms contributing Additionally, offer glimpse into landscape management near future by providing comprehensive summary upcoming early-phase trials.

Language: Английский

Citations

4
Exploring Adiposity and Chronic Kidney Disease: Clinical Implications, Management Strategies, Prognostic Considerations DOI Creative Commons
Laşin Özbek,

Sama Mahmoud Abdel‐Rahman,

S. Ünlü

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(10), P. 1668 - 1668

Published: Oct. 11, 2024

Obesity poses a significant and growing risk factor for chronic kidney disease (CKD), requiring comprehensive evaluation management strategies. This review explores the intricate relationship between obesity CKD, emphasizing diverse phenotypes of obesity, including sarcopenic metabolically healthy versus unhealthy their differential impact on function. We discuss epidemiological evidence linking elevated body mass index (BMI) with CKD while also addressing paradoxical survival benefits observed in obese patients. Various measures such as BMI, waist circumference, visceral fat assessment, are evaluated context progression outcomes. Mechanistic insights into how promotes renal dysfunction through lipid metabolism, inflammation, altered hemodynamics elucidated, underscoring role adipokines renin–angiotensin–aldosterone system. Furthermore, examines current strategies assessing function individuals, strengths limitations filtration markers predictive equations. The associated comorbidities like arterial hypertension, type 2 diabetes mellitus, non-alcoholic fatty liver patients is discussed. Finally, gaps literature future research directions aimed at optimizing obesity-related highlighted, need personalized therapeutic approaches to mitigate burden this intertwined epidemic.

Language: Английский

Citations

4
Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review DOI Open Access
Jason Zupec,

R Munger,

Alice L. Scaletta

et al.

Nutrition in Clinical Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Abstract Incretin mimetics, including glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide agonists, have become first‐line treatment options for the of type 2 diabetes obesity. Their therapeutic status is attributed to their high level efficacy as well positive impact on related comorbidities, such sleep apnea heart failure. Multiple incretin mimetics are currently available with different durations drug action, dosing frequencies, delivery devices. Patients may benefit from education proper administration, anticipated adverse effects, nutrition considerations treatment. Practitioners must monitor progress support patient achieve maintenance doses optimal weight reduction diabetes‐related outcomes. This review aims present current literature supporting US Food Drug Administration–approved indications equip healthcare professionals optimize care patients who prescribed these agents, provide insights into potential future applications, which include dual‐ or triple‐mechanism agents that injected administered orally. Additional studies existing diabetes, obesity, comorbidities in a rapidly developing pipeline.

Language: Английский

Citations

0
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review DOI Open Access
Jimmy Wen,

Denise Nadora,

Alina Truong

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Obstructive sleep apnea (OSA) is a disorder commonly secondary to obesity that has detrimental effects on health and quality of life. Thus, weight loss one the mainstays OSA treatment. Tirzepatide, novel glucagon-like peptide-1 (GLP-1) glucagon-dependent insulinotropic polypeptide (GIP) dual agonist, demonstrated significant glycemic control loss. This literature review analyzes current tirzepatide's OSA, mechanism action, complications, off-label uses/indications. Also, this offers potential insights into how tirzepatide other GLP-1 medications can be repurposed for metabolic conditions their associated sequelae.

Language: Английский

Citations

0
Inkretine für CKD-Patienten DOI
Leonie Kraft,

Jörg Latus,

Moritz Schanz

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

Citations

0
Recent Advances in Blood Glucose Management for Diabetic Patients Undergoing Hemodialysis DOI Open Access

俊杰 苏

Journal of Clinical Personalized Medicine, Journal Year: 2025, Volume and Issue: 04(02), P. 724 - 734

Published: Jan. 1, 2025

Language: Английский

Citations

0
Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus! DOI

Young Hee Lee-Barkey,

Abdulwahab Arbi,

Spasija Parizova

et al.

Gefässchirurgie, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Citations

0
Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence DOI Open Access
Ioannis Bellos,

Παγώνα Λάγιου,

Vassiliki Benetou

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(20), P. 6181 - 6181

Published: Oct. 17, 2024

This systematic review and meta-analysis aimed to evaluate the efficacy safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) glucagon-like peptide-1 receptor agonists (GLP1-RA), in diabetic kidney transplant recipients.

Language: Английский

Citations

3
GIP/GLP-1 DUAL AGONIST TIRZEPATIDE AMELIORATES RENAL ISCHEMIA/REPERFUSION DAMAGE IN RATS DOI Open Access

Ghada A. Alkhafaji,

Ali M. Janabi

International Journal of Applied Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 165 - 173

Published: March 7, 2025

Objective: Renal Ischemia/Reperfusion Injury (RIRI) initiates a cascade of deleterious events resulting in acute kidney injury with high mortality rates. Tirzepatide has anti-inflammatory, anti-apoptotic and antioxidant as well activation both autophagy Protein Kinase B (PKB or Akt) signaling pathway. This study examines the potential nephroprotective effect tirzepatide against RIRI rats. Methods: Twenty-eight male rats (Sprague Dawley) were split into four groups: sham, (IRI), Distilled Water (D. W) tirzepatide. The Sham group underwent identical procedures without bilateral renal pedicle clamping, whereas IRI was exposed to 30 min ischemia followed by 24 h reperfusion. vehicle received distilled water intraperitoneally 2 before ischemia, 3 mg/kg ischemia. Study parameters including urea, creatinine, Kidney Molecule-1 (KIM-1), interleukin-6 (IL-6), caspase-3, Akt, autophagic protein microtubule-associated 1 light chain 3-B (LC3-B) glutathione (GSH), histopathological changes examined. Results: resulted significant elevation serum creatinine levels KIM-1, IL-6, LC3-B while concurrently reduction GSH level. treatment diminished severity damage alleviating inflammatory apoptotic markers, augmenting activity improving consequences. Conclusion: elucidates effects RIRI, via its antioxidant, antiapoptotic properties Akt

Language: Английский

Citations

0